✦ LIBER ✦

A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma

✍ Scribed by Sangro, B; Mazzolini, G; Ruiz, M; Ruiz, J; Quiroga, J; Herrero, I; Qian, C; Benito, A; Larrache, J; Olagüe, C

Book ID: 109842729
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 357 KB
Volume: 17
Category: Article
ISSN: 0929-1903
DOI: 10.1038/cgt.2010.40

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/II trial of the oral antiangio

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

✍ Fumihiko Kanai; Haruhiko Yoshida; Ryosuke Tateishi; Shinpei Sato; Takao Kawabe; 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 408 KB

A phase I/II trial of TAC-101, an oral s

A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma

✍ Kimberly B. Higginbotham; Richard Lozano; Thomas Brown; Yehuda Z. Patt; Takashi 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 464 KB

Phase I clinical trial of allogeneic mix

Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound−guided fine-needle injection in patients with advanced pancreatic carcinoma

✍ Kenneth J. Chang; Phuong T. Nguyen; James A. Thompson; Thomas T. Kurosaki; Linda 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB 👁 2 views

## BACKGROUND. To the authors' knowledge, there are no other published clinical studies that have employed either systemic or local biologic response modifiers in the treatment of patients with pancreatic carcinoma. The purpose of this study was to determine the feasibility and safety of allogeneic

A phase I clinical trial of prolonged in

A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck

✍ Jonathan J. Beitler; Richard V. Smith; Hilda Haynes; Carl E. Silver; Astrid Quis 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 67 KB

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati